v2.4.0.6
Segment Information
 3 Months Ended
Mar. 31, 2012
Segment Reporting [Abstract]  
Segment Information
SEGMENT INFORMATION
We operate in one business segment, which primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.
Product sales consisted of the following (in thousands):
 
Three Months Ended
 
March 31,
 
2012
 
2011
Antiviral products:
 
 
 
Atripla
$
887,596

 
$
744,512

Truvada
758,263

 
673,111

Viread
191,693

 
168,395

Complera/Eviplera
52,180

 
—

Hepsera
29,297

 
38,096

Emtriva
6,777

 
6,576

Total antiviral products
1,925,806

 
1,630,690

AmBisome
84,764

 
78,506

Letairis
87,288

 
62,174

Ranexa
83,201

 
68,293

Other products
27,283

 
23,915

Total product sales
$
2,208,342

 
$
1,863,578


The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues): 
 
Three Months Ended
 
March 31,
 
2012
 
2011
Cardinal Health, Inc.
20
%
 
17
%
McKesson Corp.
16
%
 
15
%
AmerisourceBergen Corp.
11
%
 
13
%